Email Us : +91 33 24549650

‘Cisplatin’ in the treatment for Lung Cancer | Anzen Exports

August 1, 2021by Anzen_Exports0

Cancer is the second leading cause of death globally. ‘World Lung Cancer Day’ is observed on the 1st of August to reduce the misconceptions about cancer and raise awareness about the causes and treatments of lung cancer. This day also aims to bring people together and support cancer patients and survivors to achieve a world ‘free of cancer’.

The history of World Lung Cancer Day 

In the early 20th century, lung cancer was a rare disease, however, today it is the most common type of cancer that accounts for 12.8% of cancer cases worldwide. According to recent studies, an increase in the consumption of tobacco products and industrial products such as radiation, asbestos and uranium play a role in the development of cancer in people. Other factors such as nutritional deficiencies and air pollution also increase the risk of lung cancer. (1)

The ‘International Association for the Study of Lung Cancer’ (IASLC) hosts the world’s largest conference that is attended by more than 7,000 delegates from over 100 countries globally, to discuss the latest developments in cancer and thoracic malignancy research. This ‘World Conference on Lung Cancer’ (WCLC) helps communicate the global impact of cancers and also introduce new research, diagnoses and treatments to health professionals and patients. (2)

Efficacy of Cisplatin in NSCLC and SCLC

Cisplatin, a platinum-based chemotherapeutic drug has been used to treat a variety of cancers including the later stages of ‘Non-small-cell lung cancers’ (NSCLC). NSCLC are usually less sensitive to chemotherapy and radiation therapy. A few of the most common types of NSCLC are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma, which are mostly associated with cigarette smoke.

‘Cisplatin’ is considered one of the most effective chemotherapeutic agents used to treat patients with NSCLC. When used in combination with a ‘vinca alkaloid’ or ‘etoposide’, it has been shown to prolong survival by seven to seventeen weeks compared with no chemotherapy. (3) It has also been shown to improve survival by a greater degree in locally advanced patients in stages IIIA and IIIB when given together with chest radiotherapy. Evidence has also shown cisplatin-based chemotherapy regimens to be the most preferred systematic therapy for NSCLC patients.

‘Small-cell lung cancers’ (SCLC) are highly sensitive to chemotherapy and more aggressive than ‘non-small-cell lung cancers (NSCLC). The efficacy of Cisplatin is dose-dependent and synergistic with multiple agents. When given in combination with ‘etoposide’, it produces consistent responses as a salvage regimen for the treatment of SCLC. (4)

Your trusted partner in healthcare

Anzen Exports has been a trusted exporter and distributor of active pharmaceutical ingredients, herbal extracts and nutraceutical extracts for over three decades. We are dedicated round-the-clock to fight against diseases by keeping the consistent supply of active pharmaceutical ingredients to manufacturers of medicines.

Our constant endeavour is to touch the lives of people and update them on various diseases, precautions, medicines and well as offer them tips for healthy living. We request you to share our posts and comment on our blogs to lend us much-needed support in this noble initiative.

For more information, visit


Anzen Export’s blog posts have been written with the information gathered from approved medical journals and websites online. Our research and technical teams strive to provide relevant information through such articles. To be best informed, we advise consulting a doctor about any ingredient or medicine before taking it.


  1. Daysoftheyear [online]. Available at:
  2. IASLC [online]. Available at:
  3. Pubmed[online]. Available at:
  4. Pubmed[online]. Available at:

Leave a Reply

Your email address will not be published. Required fields are marked *


Anzen Exports

20C Hazra Road, Kolkata 700026, West Bengal,

+91 33 24549650


Follow Our Activity On


Subscribe to our Newsletter